Meril's Next-Gen Myval THV Series Marks India's Triumph in Global Heart Valve Sector: Successful Primary Outcomes Unveiled at EuroPCR 2024, Garnering Late Breaking Trial Status and Prestigious Acceptance by The LANCET
NewsVoir
Exciting news from Meril Life Sciences! The LANDMARK trial's 30 days primary outcomes were presented on 15th May at EuroPCR 2024,..